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The unique membrane-associated inhibitor of matrix
metalloproteinases, RECK, is required for vascular
maturation during embryogenesis. The phenotype of
a loss of function mutation of RECK shows the
importance of pericellular proteolysis in develop-
ment.
The complex network of proteins deposited around
cells provides more than structural scaffolding: it con-
tributes to numerous regulatory processes critical for
development and pathology, including cellular organi-
zation, growth factor availability, angiogenesis and dif-
ferentiation. Several protease families are involved in
extracellular matrix (ECM) remodeling including the
matrix metalloproteinases (MMPs) that contains 25
mouse and 22 human members [1]. MMPs can be
divided into several groups based on their structure.
Members of two of these groups contain structural
motifs including transmembrane or glycophosphatidyl
inositol-anchoring (GPI) domains that target them to
the membrane or pericellular region. The develop-
mental defect in mice lacking the MMP inhibitor,
RECK, points to the importance of regulating pericel-
lular MMP activity during development [2].
What makes RECK stand out from all other known
MMP inhibitors is its membrane localization. RECK
inhibits the activity of at least three MMP members
including MMP-9, MMP-2 and MT1-MMP [2,3]. Inter-
estingly, RECK also inhibits the release of proMMP-9
from the cell [3]. These data suggest that RECK can
inhibit MMPs through several mechanisms including
direct inhibition of protease activity, regulation of their
release from the cell and possibly through sequestra-
tion of MMPs at the cell surface.
The activity of MMPs can be regulated by several
distinct classes of proteins including the tissue
inhibitors of metalloproteinases (TIMP1–4), the
carboxy-terminal fragment of procollagen carboxy-ter-
minal proteinase enhancer (CT-PCPE), α2-macroglob-
ulin, tissue factor pathway inhibitor-2 (TFPI-2), and the
NC1 domain of collagen IV [1,4–6]. These inhibitors are
secreted and are localized to the ECM or found circu-
lating in the plasma. Although the TIMPs share only
33–51% amino acid identity, their tertiary structure is
highly similar due to the conserved positions of twelve
cysteine residues that form six disulfide bonds. Correct
pairing of the six cysteine residues in the amino termi-
nus is critical for TIMP inhibition of MMP [7,8].
The amino terminus of TIMP was recently predicted
to be homologous to domains within other proteins
having diverse functions (Figure 1). This protein motif,
coined the NTR module, has a common feature of six
conserved cysteines [9]. One predicted NTR module,
CT-PCPE, inhibited MMP in vitro. Inhibition by CT-
PCPE was hypothesized to occur because the folded
structure of CT-PCPE was similar to TIMP [6]. Whether
other NTR proteins such as Netrin and the secreted
Frizzled-related proteins have MMP inhibitory activity
remains to be determined. However it should be noted
that chemical inhibitors of metalloproteinase activity
synergize with Netrin as an axonal chemoattractant
[10].
The mechanism by which TFPI-2 inhibits MMP is
not clear. Although TFPI-2 does not seem to have a
classic NTR module, there is a region within TFPI-2
containing a number of cysteine residues that aligns
reasonably well with the amino-terminal domain of
TIMP and NTR module polypeptides (Figure 1). RECK
also contains a number of cysteine residues, however,
comparison of the RECK amino acid sequence to
TIMP and the NTR module does not show robust sim-
ilarities. Thus, the biochemical mechanism for RECK
inhibition of MMP remains to be elucidated
One of the unique features of RECK is that it con-
tains a GPI domain making it a novel membrane-tar-
geted MMP inhibitor. The targeting of several MMP
Dispatch
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Figure 1. Alignment of TIMP with CT-PCPE, Netrin, secreted
Frizzled related proteins and TFPI-2.
The human NTR modules [8] of the four TIMPs were aligned
with the NTR modules of human CT-PCPE, human Netrin 2-like
protein and secreted Frizzled-related proteins (human-secreted
apoptosis-related protein, SARP-2 and SARP-3) and an internal
region of TFPI-2. Sequence analysis was done using MultAlin
[19] with a PAM250 scoring matrix in the web based resources
of the Sequence Analysis and Consulting Service, a part of the
Computer Graphics Laboratory at the University of California
San Francisco. A consensus sequence is shown on the bottom
line. High consensus amino acids are capitalized in red. Low
consensus amino acids are lower case in blue. The symbol %
is either F or Y.
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TIMP-1     C--TCVPPHPQ-----TAFCNSDLVIRAKFVGTPE---V--NQTTYQ------RYEIKMTKMYKGFQA---LGDAADIR-FVYTPAMESV
TIMP-2     C--SCSPVHPQ-----QAFCNADVVIRAKAVSEKE---VDSGNDIYGNPIKRIQYEIKQIKMFKGPEK--------DIE-FIYTAPSSAV
TIMP-3     C--TCSPSHPQ-----DAFCNSDIVIRAKVVGKKL---V--KEGPFGT----LVYTIKQMKMYRGFTK---M---PHVQ-YIHTEASESL
TIMP-4     C--SCAPAHPQ-----QHICHSALVIRAKISSEKV---VPASADPADTE-KMLRYEIKQIKMFKGFEK---V---KDVQ-YIYTPFDSSL
TFPI-2     CDDACWRIEKV-----PKVCRLQVSVDDQCEGSTEKYFFNLSSMTCEKFFSGGCHRNRIENRFPDEATCMGFCAPKKIPSFCYSPKDEGL
CT-PCPE    CPKQCRRT-GTLQ---SNFCASSLVVTATVKSMVR------EPGEGL-----AV-TVSLIGAYKTGGL-----DLPSPPTGASLKF-YVP
netrin-2L  CDSHCKPARGSYRISLKKFCKKDYAVQVAVGARGE------ARGAWT-----RF-PVAVLAVFRSGEE-----RARRGSSALWVPAGDAA
sarp-2     CP-PCDNELKSEAI-IEHLCASEFALRMKIKEVKK------ENGDKK-----IV--PKKKKPLKLGPI-----KKKDLKKLVLYLKNGAD
sarp-3     CA-QCEMEHSADGL-MEQMCSSDFVVKMRIKEIKI------ENGDRK-----LIGAQKKKKLLKPGPL-----KRKDTKRLVLHMKNGAG
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TIMP-1     CG-----YFHRSHNRS-EEFLIAGKL--------Q-DGL-LHITTCS--FVAPWNSLSLAQRRGFTKTYTV----GC
TIMP-2     CG-----VSLDVGGKK-E-YLIAGKA--------EGDGK-MHITLCD--FIVPWDTLSTTQKKSLNHRYQM----GC
TIMP-3     CG-----LKLEVN-KY-Q-YLLTGRV--------Y-DGK-MYTGLCN--FVERWDQLTLSQRKGLNYRYHL----GC
TIMP-4     CG-----VKLEANSQK-Q-YLLTGQV--------LSDGK-VFIHLCN--YIEPWEDLSLVQRESLNHHYHL----NC
TFPI-2     CSANVTRYYFNPRYRTCDAFTYTGCG--------GNDNNFVSREDCKRACAKALKKKKKMPKLRFASRIRKIRKKQF
CT-PCPE    CKQC---PPMKK-GVS---YLLMGQV-------EENRGPVL-PPESF--VVLHRPNQ-DQILTNLSKR-------KC
netrin-2L  C-GC---PRLLP-GRR---YLLLGGGPGAAAGGAGGRGPGLIAARGS--LVLPWRDAWTRRLRRLQRRERR---GRC
sarp-2     C-PC---HQLDNLSHH---FLIMGR---------KVKSQYLLTA------IHKWDKK-NKEFKNFMKKMKN---HEC
sarp-3     C-PC---PQLDSLAGS---FLVMGR---------KVDGQLLLMA------VYRWDKK-NKEMKFAVKFMFS---YPC
Consensus  C        l         %l  G            dg  l    c    v  w          l  r        c
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family members to the pericellular region either by a
direct membrane anchor, or by receptors or binding
proteins at the cell surface, creates a region of con-
centrated proteolytic activity that may function in cell
invasion as well as during localized growth factor sig-
naling by modulating ECM–ligand interactions. Fur-
thermore, the activation of some MMPs requires an
interaction with certain membrane-associated MMPs.
This paradigm has been nicely established for the
activation of MMP-2 by the membrane associated
MT1-MMP, a process which is regulated by both
RECK and TIMP-2 (Figure 2).
Interestingly, TIMP-2 has two functions during
MMP-2 activation, each confined to a distinct domain:
as an MMP inhibitor through its amino-terminal
domain which can bind to MT1-MMP; and as an MMP
activator via its carboxy-terminal domain that recruits
proMMP-2 to form a ternary complex which results in
activation of MMP-2 (Figure 2). The effect of pericellu-
lar targeting positions RECK at the site of vigorous
proteolytic activity that may potentiate its inhibitory
ability (Figure 2). Furthermore, the GPI anchoring 
of RECK may target it to distinct cellular regions
including caveolae or regions of cell adhesion, thus
positioning it at critical sites involved in cell signaling.
It is unknown whether RECK has other long-range
functions as a consequence of its release from the cell
surface by GPI cleaving enzymes such as glyco-
sylphosphatidylinositol phospholipase C. These char-
acteristics may, in part, explain some of the more
profound developmental defects observed in RECK
knockout mice when compared with the mild devel-
opmental phenotypes described for TIMP-1, TIMP-2,
TIMP-3 and α2-macroglobulin knockout mice [11–14].
Vascular development is a key process that must
occur for embryonic development to proceed. The
balance between ECM breakdown and deposition is
critical for endothelial cell homeostasis and con-
tributes to vasculogenesis and angiogenesis. During
vasculogenesis, periendothelial cells proliferate and
migrate to form networks of immature vessels. Mural
cells (precursor pericytes) stimulate vascular matura-
tion by stabilizing nascent vessels through the depo-
sition of ECM [15]. The ECM can have multiple effects
on endothelial cells including inhibiting proliferation
and migration suggesting that modulating MMP pro-
cessing and proteolytic activity is critical for vascular
maturation. Indeed, during development RECK is
expressed in large blood vessels and mural cells [2]
similar to the pericyte marker smooth muscle α-actin.
Thus expression of RECK in pericytes positions it to
elicit potent and concentrated inhibitory effects on
MMP-9, MT1-MMP and MMP-2 activity near endothe-
lial cells.
In the absence of RECK, increased proteolytic activ-
ity would be expected to result in ECM degradation
and the destabilization of nascent vessels. This effect
is seen in reck-/- embryos that display an embryonic
lethality at about 10.5 days and a defect in vascular
maturation [2]. Moreover, it is noteworthy that embry-
onic survival can be extended by one day, a significant
delay at this critical stage of vascular development,
when reck-/- mice are bred into the MMP-2-/- back-
ground suggesting that abrogating MMP-2 activity par-
tially rescues the phenotype [2]. The question remains
as to whether activity of the other two MMPs — MMP-
9 and MT1-MMP — can account for the remaining
phenotype, or whether RECK has other enzymatic
targets such as other MMPs, or members of the met-
alloproteinase superfamily such as ADAMs, ADAM-TSs
or Tolloid-related Astascins [2].
One function of the ECM — once thought to be its
only function — is to provide a physical barrier between
tissue compartments. ECM is also an important reser-
voir of growth, differentiation and angiogenic factors,
and cleavage of ECM can produce fragments that
have distinct biological activities [16]. During invasive
developmental growth, for example during angiogen-
esis, restructuring of the ECM is required for blood
vessel migration and intrusion into neighboring tissue.
ECM degradation also occurs during pathological
events including tumor growth and invasion, and ECM
degrading proteases such as MMPs are involved in
these processes. Upregulated MMP expression is
seen in almost all human cancers and their expression
generally correlates with poor prognosis and with
malignant transformation [17]. The converse correlation
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Figure 2. RECK can modulate the activity of MT1-MMP, MMP-
2 and MMP-9 through several mechanisms.
(A) MT1-MMP is involved in the processing of proMMP-2 to
produce mature MMP-2. During this process, TIMP-2 bridges
MT1-MMP with proMMP-2. A second MT1-MMP molecule
cleaves a portion of the prodomain on MMP-2 to form an inter-
mediate MMP-2 protein. Further cleavage of MMP-2’s
prodomain by a different membrane associated MMP results in
the final maturation and release of MMP-2 from the cell surface.
Both of these processes can be inhibited by RECK. (B) RECK
can also inhibit MMP-9’s activity and its release from the cell
through an unknown mechanism. Thus, RECK directly regu-
lates MMP activity and can indirectly modulate localized
growth factor availability.
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with cancer would be predicted for the expression of
TIMPs. However, this is not necessarily the case as
elevated TIMP expression is observed in several
human cancers and its detection often correlates with
poor prognosis [17]. Indeed, conflicting data exist on
TIMP expression and tumorigenesis in both mouse
models and human cancers [1]. TIMPs may have mul-
tiple roles, including activating and inhibiting MMP
activity as well as MMP-independent influences,
depending on which TIMPs are expressed and their
expression levels.
While the role of TIMPs in tumorigenesis may be
somewhat confusing, MMP activity, particularly peri-
cellular activity, appears vital for tumor angiogenesis.
When RECK is expressed in human fibrosarcoma cells
and these cells are transplanted into nude mice, tumors
arise that have angiogenic defects [2]. These data
suggest that the loss of RECK expression in tumor cells
enhances angiogenesis. However, although RECK is
attached to the membrane its sphere of influence
appears widespread; it is capable of mediating effects
between tumor cells and the vascular endothelium. This
broad effect is most likely a result of RECK’s multifac-
eted ability to regulate MMP-9 secretion, and inhibit
MT1-MMP and MMP-2 activity at the cell surface (see
Figure 2). As MT1-MMP is the major activator of MMP-
2, RECK’s inhibitory ability is, in essence, amplified.
From gain-of function and loss-of-function experi-
ments, Oh et al. [2] predict a model in which RECK is
required for vascular development, yet too much RECK
could block sprouting angiogenesis by inhibiting
endothelial cell invasion through surrounding ECM.
Is RECK a tumor suppressor? RECK was originally
identified as a gene that can revert the transforming
phenotype of ras transformed NIH3T3 cells [3]. Inter-
estingly, RECK mRNA expression in culture is inhib-
ited by ras as well as by several other oncogenes
commonly found altered in tumors including myc,
mos, fos and src [3]. Furthermore, RECK expression is
low or absent in several tumor cell lines, and RECK
reduces invasiveness and metastatic potential when
transfected into metastatic fibrosarcoma and
melanoma cells lines [3]. In human hepatocellular car-
cinoma samples, RECK expression correlates with
less invasive tumors as well as better prognostic
outcome [18]. Further genetic analysis of RECK in
human tumors is needed to determine if this gene is
truly a tumor suppressor, but with the limited data we
already have, it is intriguing to speculate that an MMP
inhibitor may one day obtain this classification.
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